GT Biopharma (NASDAQ:GTBP) Trading 5.1% Higher – Should You Buy?

Posted by Francis Steltz on Aug 4th, 2026

GT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report) was up 5.1% on Monday . The company traded as high as $0.3156 and last traded at $0.3086. Approximately 418,806 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 780,414 shares. The stock had previously closed at $0.2935.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of GT Biopharma to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings restated a “sell (e+)” rating on shares of GT Biopharma in a research note on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

View Our Latest Research Report on GT Biopharma

GT Biopharma Stock Performance

The firm has a fifty day simple moving average of $0.42 and a 200-day simple moving average of $0.45. The company has a market capitalization of $13.68 million, a PE ratio of -0.05 and a beta of 0.90.

GT Biopharma (NASDAQ:GTBP – Get Free Report) last released its earnings results on Friday, May 15th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). As a group, research analysts anticipate that GT Biopharma, Inc. will post -0.34 EPS for the current fiscal year.

Hedge Funds Weigh In On GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. Everhart Financial Group Inc. acquired a new stake in GT Biopharma, Inc. (NASDAQ:GTBP – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 100,000 shares of the company’s stock, valued at approximately $49,000. Everhart Financial Group Inc. owned about 0.23% of GT Biopharma as of its most recent SEC filing. Hedge funds and other institutional investors own 8.15% of the company’s stock.

GT Biopharma Company Profile

(Get Free Report)

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).